Granulocyte-colony stimulating factor improves the survival of ischaemic skin flaps by the induction of angiogenesis

被引:1
作者
Sari, Alper [1 ]
Gurbuz, Onur [1 ]
Yilmaz, Necat [2 ]
Eskandari, Gulcin [3 ]
Tasdelen, Bahar [4 ]
Basterzi, Yavuz [1 ]
机构
[1] Mersin Univ, Fac Med, Dept Plast & Reconstruct Surg, Mersin, Turkey
[2] Mersin Univ, Fac Med, Dept Histol & Embryol, Mersin, Turkey
[3] Mersin Univ, Fac Med, Dept Biochem, Mersin, Turkey
[4] Mersin Univ, Fac Med, Dept Biostat, Mersin, Turkey
关键词
Flap survival; Ischaemia; Colony stimulating factor; Angiogenesis; G-CSF; CELLS; GROWTH; RATS; NEOVASCULARIZATION; TRANSPLANTATION; MOBILIZATION; ULCERS;
D O I
10.1016/j.bjps.2008.02.006
中图分类号
R61 [外科手术学];
学科分类号
摘要
In this study the effects of granulocyte-colony stimulating factor (G-CSF) on angiogenesis and the survival of ischaemic skin flaps are evaluated. Thirty adult Wistar rats were equally randomised into three groups. Caudal-based, ischaemic skin flaps of 10 x 3 cm were designed on the back and injected with saline in group I and with 100 mu g/kg G-CSF in groups 2 and 3. The injections were performed just prior to flap elevation in groups 1 and 2 and 2 days earlier in group 3. Peripheral leukocyte counts, tissue myeloperoxidase enzyme assays, necrotic to total flap area ratio (NA/TA) calculations, flap tissue inflammation gradings, immunohistochemical vessel counts, and electron microscopic evaluation of endothelial cells were performed on the 8th day. No significant difference was encountered between the groups in terms of the leukocyte counts, myeloperoxidase enzyme assays and inflammation gradings (P > 0.05), demonstrating the absence of an increased inflammatory response within the flap tissue. The surviving flap portions were observed to be increased with the application of G-CSF. The mean NA/TA results (when measured in situ) were 0.44 +/- 0.13 for group 1, 0.30 +/- 0.17 for group 2, and 0.22 +/- 0.16 for group 3. The difference between groups 1 and 3 was statistically significant (P = 0.009). The mean vessel count was 3.53 +/- 1.20 in group 1, 7.36 +/- 1.41 in group 2 and 7.43 +/- 0.92 in group 3. The differences between groups 1 and 2 and groups 1 and 3 were statistically significant (P <= 0.001). Early apoptotic changes were encountered in the endothelial cells of group 1, while activated and proliferating endothelial cells were seen in groups 2 and 3 with electron microscopy. G-CSF promotes angiogenesis by increasing the number of activated and proliferating endothelial cells within the ischaemic flaps by the resettlement of G-CSF-stimulated endothelial progenitor cells into the ischaemic tissue. The overall result is an improved survival of ischaemic skin flaps. These effects are more pronounced when G-CSF is introduced 2 days prior to flap elevation. (C) 2008 Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons.
引用
收藏
页码:1035 / 1041
页数:7
相关论文
共 50 条
  • [21] Effects of granulocyte-colony stimulating factor on bone marrow-derived progenitor cells in murine cardiac transplantation
    Rezai, Nana
    Deisher, Theresa A.
    Heine, Heather L.
    Wang, Xiaozhen
    Corbel, Stephane Y.
    Leung, Joanna
    Kerjner, Alexandra
    Rossi, Fabio M. V.
    Podor, Thomas J.
    McManus, Bruce M.
    CARDIOVASCULAR PATHOLOGY, 2010, 19 (01) : 36 - 47
  • [22] The role of follistatin and granulocyte-colony stimulating factor in HIV-associated pre-eclampsia
    Mdlalose, Siphesihle
    Moodley, Jagidesa
    Naicker, Thajasvarie
    PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2020, 19 : 81 - 86
  • [23] The Granulocyte-colony stimulating factor has a dual role in neuronal and vascular plasticity
    Wallner, Stephanie
    Peters, Sebastian
    Pitzer, Claudia
    Resch, Herbert
    Bogdahn, Ulrich
    Schneider, Armin
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2015, 3
  • [24] Preoperative Granulocyte-Colony Stimulating Factor (G-CSF) Treatment Improves Congested Liver Regeneration
    Kimura, Masaki
    Yamada, Takuya
    Iwata, Hisashi
    Sekino, Takafumi
    Shirahashi, Kouyou
    Yoshida, Naomasa
    Kiyama, Shigeru
    Takemura, Hirofumi
    JOURNAL OF SURGICAL RESEARCH, 2010, 158 (01) : 132 - 137
  • [25] Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary
    Hornyak, Lajos
    Nagy, Zsolt
    Ilku, Livia
    Talos, Zsuzsanna
    Endrei, Dora
    Agoston, Istvan
    Csakvari, Timea
    Danku, Nora
    Repasy, Balazs
    Boncz, Imre
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (06) : 725 - 731
  • [26] New treatment with granulocyte-colony stimulating factor in diabetic foot ulceration
    Kreyden, OP
    Hafner, J
    Burg, G
    Nestle, FO
    HAUTARZT, 2001, 52 (04): : 327 - 330
  • [27] Effects of Granulocyte-Colony Stimulating Factor After Stroke in Aged Rats
    Popa-Wagner, Aurel
    Stoecker, Kai
    Balseanu, Adrian Tudor
    Rogalewski, Andreas
    Diederich, Kai
    Minnerup, Jens
    Margaritescu, Claudiu
    Schaebitz, Wolf-Ruediger
    STROKE, 2010, 41 (05) : 1027 - 1031
  • [28] The effect of granulocyte-colony stimulating factor in global cerebral ischemia in rats
    Matchett, Gerald A.
    Calinisan, Jason B.
    Matchett, Genoveve C.
    Martin, Robert D.
    Zhang, John H.
    BRAIN RESEARCH, 2007, 1136 (01) : 200 - 207
  • [29] Effect of serum deprivation on constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells
    Uemura, Y
    Kobayashi, M
    Nakata, H
    Harada, R
    Kubota, T
    Taguchi, H
    INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (06) : 826 - 832
  • [30] Granulocyte-Colony Stimulating Factor as Treatment Option in Patients with Recurrent Miscarriage
    Santjohanser, Claudia
    Knieper, Catherine
    Franz, Cordula
    Hirv, Kaino
    Meri, Osama
    Schleyer, Manfred
    Wuerfel, Wolfgang
    Toth, Bettina
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2013, 61 (02) : 159 - 164